Another newly discovered subtype of HR proficient high-grade serous ovarian cancer has amplifications in the bromodomain and extraterminal 4 gene (BRD4) and is similarly associated with poor outcomes [18,20]. This evidence concerns the gene BRD4 and ovarian serous adenocarcinoma.